Literature DB >> 21727939

Multiple sclerosis: MS treatment adherence--how to keep patients on medication?

Jared M Bruce, Sharon G Lynch.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21727939     DOI： 10.1038/nrneurol.2011.106

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN： 1759-4758            Impact factor:   42.937


× No keyword cloud information.
  9 in total

1.  Adherence to multiple sclerosis disease-modifying therapies in Ontario is low.

Authors:  Janice Wong; Tara Gomes; Muhammad Mamdani; Michael Manno; Paul W O'Connor
Journal:  Can J Neurol Sci       Date:  2011-05       Impact factor: 2.104

2.  Non-adherence to interferon-beta therapy in Swedish patients with multiple sclerosis.

Authors:  A Cunningham; K Gottberg; L von Koch; J Hillert
Journal:  Acta Neurol Scand       Date:  2010-01-06       Impact factor: 3.209

3.  Adherence to disease-modifying therapy in multiple sclerosis: Part II.

Authors:  N Holland; P Wiesel; P Cavallo; C Edwards; J Halper; R Kalb; L Morgante; M Namey; M O'Leary; L Smith-Williamson
Journal:  Rehabil Nurs       Date:  2001 Nov-Dec       Impact factor: 1.625

4.  Objective adherence monitoring in multiple sclerosis: initial validation and association with self-report.

Authors:  Jared M Bruce; Laura M Hancock; Sharon G Lynch
Journal:  Mult Scler       Date:  2009-12-07       Impact factor: 6.312

5.  Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis.

Authors:  D C Mohr; D E Goodkin; W Likosky; N Gatto; K A Baumann; R A Rudick
Journal:  Arch Neurol       Date:  1997-05

6.  Evaluation of software-based telephone counseling to enhance medication persistency among patients with multiple sclerosis.

Authors:  Bruce A Berger; Huigang Liang; Karen Suchanek Hudmon
Journal:  J Am Pharm Assoc (2003)       Date:  2005 Jul-Aug

7.  Treatment adherence in multiple sclerosis: association with emotional status, personality, and cognition.

Authors:  Jared M Bruce; Laura M Hancock; Peter Arnett; Sharon Lynch
Journal:  J Behav Med       Date:  2010-02-03

8.  Persistence and adherence to disease modifying drugs among patients with multiple sclerosis.

Authors:  Matthew W Reynolds; Reejis Stephen; Chris Seaman; Kitty Rajagopalan
Journal:  Curr Med Res Opin       Date:  2010-03       Impact factor: 2.580

9.  Disease-modifying therapy in multiple sclerosis: update and clinical implications.

Authors:  Douglas S Goodin
Journal:  Neurology       Date:  2008-12-09       Impact factor: 9.910
  9 in total
  8 in total

1.  Immunotherapy for people with clinically isolated syndrome or relapsing-remitting multiple sclerosis: treatment response by demographic, clinical, and biomarker subgroups (PROMISE)-a systematic review protocol.

Authors:  Thomas Lehnert; Christian Röver; Sascha Köpke; Jordi Rio; Declan Chard; Andrea V Fittipaldo; Tim Friede; Christoph Heesen; Anne C Rahn
Journal:  Syst Rev       Date:  2022-07-01

2.  Role Preferences of People with Multiple Sclerosis: Image-Revised, Computerized Self-Administered Version of the Control Preference Scale.

Authors:  Alessandra Solari; Andrea Giordano; Jurgen Kasper; Jelena Drulovic; An van Nunen; Liina Vahter; Frederique Viala; Erika Pietrolongo; Maura Pugliatti; Carlo Antozzi; Davide Radice; Sascha Köpke; Christoph Heesen
Journal:  PLoS One       Date:  2013-06-18       Impact factor: 3.240

3.  Evaluator-blinded trial evaluating nurse-led immunotherapy DEcision Coaching In persons with relapsing-remitting Multiple Sclerosis (DECIMS) and accompanying process evaluation: study protocol for a cluster randomised controlled trial.

Authors:  Anne Christin Rahn; Sascha Köpke; Jürgen Kasper; Eik Vettorazzi; Ingrid Mühlhauser; Christoph Heesen
Journal:  Trials       Date:  2015-03-21       Impact factor: 2.279

4.  Conjoint analysis to understand preferences of patients with multiple sclerosis for disease-modifying therapy attributes in Spain: a cross-sectional observational study.

Authors:  Rafael Arroyo; Angel P Sempere; Elena Ruiz-Beato; Daniel Prefasi; Agata Carreño; Montse Roset; Jorge Maurino
Journal:  BMJ Open       Date:  2017-03-08       Impact factor: 2.692

5.  Reasons for discontinuation of subcutaneous interferon β-1a three times a week among patients with multiple sclerosis: a real-world cohort study.

Authors:  Meritxell Sabidó-Espin; Rick Munschauer
Journal:  BMC Neurol       Date:  2017-03-23       Impact factor: 2.474

6.  Beliefs about medication as predictors of medication adherence in a prospective cohort study among persons with multiple sclerosis.

Authors:  Efrat Neter; Lea Glass-Marmor; Anat Wolkowitz; Idit Lavi; Ariel Miller
Journal:  BMC Neurol       Date:  2021-03-25       Impact factor: 2.474

7.  Effect of Mindfulness-Based Stress Reduction on Anxiety, Depression and Stress in Women With Multiple Sclerosis.

Authors:  Bentolhoda Kolahkaj; Fatemeh Zargar
Journal:  Nurs Midwifery Stud       Date:  2015-12-01

8.  Psychometric properties of the SDM-Q-9 questionnaire for shared decision-making in multiple sclerosis: item response theory modelling and confirmatory factor analysis.

Authors:  Javier Ballesteros; Ester Moral; Luis Brieva; Elena Ruiz-Beato; Daniel Prefasi; Jorge Maurino
Journal:  Health Qual Life Outcomes       Date:  2017-04-22       Impact factor: 3.186
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.